Evaluation of Patients for Radiotherapy for Prostate Adenocarcinoma

Prostate adenocarcinoma is the most common non-cutaneous malignancy among men in the United States, and the second leading cause of death. However, most prostate adenocarcinoma diagnoses are now diagnosed at early stages and are curable, or if they recur, are associated with such long survival times that the patients usually succumb to competing co-morbidities. This chapter would discuss a brief history of prostate cancer evaluation and its pertinence today, including the Gleason scoring system, advent of PSA testing, and development of the NCCN classification system that is used today. Alternative classification systems, such as the UCSF-CAPRA scoring system, would also be discussed. The latter half of the chapter will discuss the evolution from personalized medicine to precision medicine, including PSMA imaging and prostate cancer genomics, with ongoing trials and future directions. Furthermore, included within this chapter would be a discussion of selecting appropriate men for active surveillance, and appropriate regimens for active surveillance

AI is a viable alternative to high throughput screening: a 318-target study

: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery

Assumption without representation: the unacknowledged abstraction from communities and social goods

We have not clearly acknowledged the abstraction from unpriceable “social goods” (derived from communities) which, different from private and public goods, simply disappear if it is attempted to market them. Separability from markets and economics has not been argued, much less established. Acknowledging communities would reinforce rather than undermine them, and thus facilitate the production of social goods. But it would also help economics by facilitating our understanding of – and response to – financial crises as well as environmental destruction and many social problems, and by reducing the alienation from economics often felt by students and the public

War crimes research symposium : terrorism on trial (tape 3 of 4)

Lecture series 2004-05. Symposium presented at Franklin Thomas Backus School of Law (Case Law School) on Friday, Oct. 8, 2004. Symposium co-chairs: Professor Michael P. Scharf (director, Frederick K. Cox International Law Center) and Lt. Col. Amos Guiora (Israel defense forces; visiting professor at Case Law School) Panelists: KEYNOTE ADDRESS: David Andrews (senior vice president of government affairs, PepsiCo Inc. & legal adviser to the U.S. Department of State during the Clinton administration); PANEL ONE: Lt. Col. Amos Guiora (Israel defense forces, visiting professor), Mark Drumbl (professor, Washington & Lee College of Law), Mary Ellen O\u27Connell (professor, Ohio State University College of Law); LUNCH PANEL: Nickolas Rostow (Chief Counsel, U.S. Mission to the U.N.), Alex Schmid (Senior crime prevention & criminal justice officer, terrorism prevention branch, U.N., Vienna, Austria), Bruce Broomhall, (professor of criminal law, University of Quebec); PANEL THREE: Robert Black (Queens Counsel, Professor of Scots Law, University of Edinburgh), Julian Knowles (Barrister at law, Matrix Chambers, London, England & Lockerbie Appeal Defense Counsel); Steve Emerson (Executive director, Investigate Project & author, The Fall of Pan Am 103 ); PANEL FOUR: Mark Zaid (Plaintiffs\u27 counsel representing victims\u27 families, Pan Am 103 v. Libya), Robert Mirone (Lead Defense Counsel for Libya, Pan Am 103 civil proceedings), Alan Gerson (author, The price of terror & former assistant attorney general & chief counsel, U.S. Mission to the U.N.); PANEL FIVE: Jonathan Leiken (Professor, Case School of Law, former Assistant U.S. Attorney, SDNY), Andrew McCarthy (former chief prosecutor, WTC bombing case), Toni Locy (Journalist, USA Today), Greg Noone (Program officer, U.S. Institute of Peace), Judge Evan Wallach (Court of International Trade), Scott Silliman (Professor & executive director, Duke University Center on Law, Ethics, & National Security) Contents: panel 1: use of force versus use of courts in the war on terrorism -- lunch panel: Is terrorism worth defining? -- panel 3: lessons learned from the Pan Am 103 bombing trial -- panel 4: suing terrorists in U.S. court -- panel 5: the trials of al Qaeda: federal court versus military commissio